These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16249086)

  • 21. Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis.
    Papadopoulou A; Menegola M; Kuhle J; Ramagopalan SV; D'Souza M; Sprenger T; Radue EW; Kappos L; Yaldizli Ö
    Mult Scler; 2014 Mar; 20(3):322-30. PubMed ID: 23846352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study.
    Zhang Y; Traboulsee A; Zhao Y; Metz LM; Li DK
    Mult Scler; 2011 May; 17(5):532-40. PubMed ID: 21270058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
    J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study.
    Sinnecker T; Mittelstaedt P; Dörr J; Pfueller CF; Harms L; Niendorf T; Paul F; Wuerfel J
    Arch Neurol; 2012 Jun; 69(6):739-45. PubMed ID: 22351849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study.
    Oreja-Guevara C; Rovaris M; Iannucci G; Valsasina P; Caputo D; Cavarretta R; Sormani MP; Ferrante P; Comi G; Filippi M
    Arch Neurol; 2005 Apr; 62(4):578-84. PubMed ID: 15824256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
    Romine JS; Sipe JC; Koziol JA; Zyroff J; Beutler E
    Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
    Min M; Spelman T; Lugaresi A; Boz C; Spitaleri D; Pucci E; Grand'Maison F; Granella F; Izquierdo G; Butzkueven H; Sanchez-Menoyo JL; Barnett M; Girard M; Trojano M; Grammond P; Duquette P; Sola P; Alroughani R; Hupperts R; Vucic S; Kalincik T; Van Pesch V; Lechner-Scott J
    Mult Scler; 2018 Oct; 24(12):1569-1577. PubMed ID: 30234431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identical lesion morphology in primary progressive and relapsing-remitting MS--an ultrahigh field MRI study.
    Kuchling J; Ramien C; Bozin I; Dörr J; Harms L; Rosche B; Niendorf T; Paul F; Sinnecker T; Wuerfel J
    Mult Scler; 2014 Dec; 20(14):1866-71. PubMed ID: 24781284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Clin Neurol Neurosurg; 2014 Apr; 119():17-20. PubMed ID: 24635919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapsing-remitting tumefactive multiple sclerosis.
    Selkirk SM; Shi J
    Mult Scler; 2005 Dec; 11(6):731-4. PubMed ID: 16320737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.